<img alt="" src="https://secure.agile-company-247.com/261975.png" style="display:none;">

Startup Stage


Hosted by:

Eli Lilly Logo

Designed exclusively for pre-series A biotech, medtech or healthtech companies.

 

10:30

Investing in the Future of the European Life Sciences: Maintaining Global Leadership and Expanding Abroad

At the forefront of breakthrough treatments of disease, life science business rely tremendously on funding and capital. The discovery and development of new drugs, vaccines and cell/gene therapies have placed life sciences at the frontier of responses to global challenges and new investments. These include the increasing access to digital health, ageing populations and the provision of sustainable healthcare.

  • With the advent of newer fund managers with strong life science pedigrees to both the UK, and Global Investor Ecosystems, what are the impacts on investments both home and abroad?
  • How can funds work to support the next generation of biotechs and founders?
  • How can new fund managers work collectively to ensure the longevity of investment in life sciences worldwide

Moderator: Laura Lane, VP - Venture Sciences (Europe), Eli Lilly and Company
Anne Horgan
, Partner, CIC
Tim Funnell
, Partner, Monograph Capital

Laura Lane, VP Venture Sciences - Europe, LillyAnne Horgan, Partner, Cambridge Innovation CapitalTim Funnell, Partner, Monograph Capital


11:05 PRAMOMOLECULAR Logo

11:15 Antikor Logo

 


11:25 Gendius Logo

 


11:35 Lifespin GmbH Logo

 


11:45 Monument Therapeutics Logo

 


11:55 Curileum Discovery Logo

 


12:05 Enbiosis Biotechnology Logo

 


12:15 Medherant Logo

 


12:25 4Tissue Logo

 


12:35 Ilonov Logo

 


12:45 LAM-X Logo

 


12:55 ExtraHorizon Logo

 


13:05 Zylorion Health Logo

 


13:15 HookeBio Logo

 


13:25 FerryX Logo

 


13:35 Antion Biosciences Logo

 


13:45

The Promise of Late-Stage Neuroscience Assets and What This Could Mean for the Financing Landscape of Early-Stage CNS Companies

Recognition that ageing populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Dementia is the most common degenerative neurological condition in the United States, with most cases coming from Alzheimer’s disease. In 2021, 653 clinical development programs for medicines to treat neurological diseases, 43% of which are for neurodegenerative medicines. On top of this, recent advances in genomics and immunology and new diagnostics and surgeries, are unlocking radical progress in neuroscience this decade akin to the genomics revolution of the past two decades.

  • Where are the current areas of highest unmet need in neuroscience? Has the pandemic affected how neuroscience assets are viewed?
  • How have recent advancements, developments and work towards long-elusive approvals in NGD reframed the landscape?
  • Which new innovations in biotechnology are fuelling novel drug discovery and development in neuroscience and how is this affecting allocation of capital?
  • How are funds being restructured and what new funds are helping to accelerate this new wave of advancements?
  • Which new innovations are fuelling novel drug discovery and development and how is this affecting allocation of capital into the space?

Moderator: Jenny Laird, VP, Search & Evaluation, Eli Lilly and Company Limited
Olivia Cavlan, Chief Corporate Development & Strategy Officer, Alchemab
Felice Verduyn-Van-Weegen, Partner, EQT Group
Hugh Nuthall, Senior Director, Search & Evaluation Neuroscience, Eli Lilly and Company
David Reynolds
, CEO, LoQus 23

Jenny Laird, VP Search & Evaluation, LillyOlivia Cavlan, Chief Corporate Development & Strategy Officer, AlchemabFelice Verduyn-Van-Weegen, Partner, EQT GroupHugh Nuthall, Senior Director, Search & Evaluation Neuroscience, Eli Lilly and CompanyDavid Reynolds, CEO, LoQus 23


14:25 Hybridize Therapeutics Logo

 


14:35 Helex Logo

 


14:45 InStar Technologies Logo

 


14:55 Repair Biotechnologies Logo

 


15:05 Imophoron Logo

 


15:15 Sedivention Logo

 


15:25 Tediro Logo

 


15:35 ICHORtec Logo

 


15:45 Temisis Logo

 


15:55 NanoVation Therapeutics Logo

 


16:05 Nevragenics Logo

 


16:15 Captain T Cell Logo

 


16:25 Astrivax Logo

 


16:35 CyGenica Logo

 


16:45 PainDrainer Logo

 


16:55 Medical Magnesium Logo

 


17:05 Valo Therapeutics Logo

 


17:15 Close of Investival Showcase

18:30

Lifestars Logo

Awards & Gala Dinner
- Separate ticket required
- Find out more

DOWNLOAD BROCHURE